# OnCo record daratumumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/daratumumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "daratumumab" ;
  schema:name "Daratumumab"@en ;
  schema:description "The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing."@en ;
  schema:url <https://onco.cc/drugs/daratumumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Daratumumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5222113> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Daratumumab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-CD38)" ;
  schema:alternateName "Darzalex / Darzalex Faspro (SC)" ;
  onco:approval "US 2015: Relapsed myeloma after ≥3 lines", "US 2019: Newly diagnosed, transplant-ineligible with Rd (MAIA) and VMP", "US 2024: Newly diagnosed transplant-eligible with VRd (PERSEUS)", "US 2026: With teclistamab after ≥1 line (MajesTEC-3); high-risk smouldering myeloma (AQUILA)" ;
  onco:acceleratedApproval "US 2015-11-16: Multiple myeloma after at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or double refractory to a proteasome inhibitor and an immunomodulatory agent", "US 2021-01-15: Treatment of patients with light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients" ;
  onco:acceleratedApprovalConfirmed "US 2016-11-21: Multiple myeloma after at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or double refractory to a proteasome inhibitor and an immunomodulatory agent", "US 2025-11-19: Treatment of patients with light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/smouldering-myeloma/>, <https://onco.cc/cancers/myeloma-transplant-eligible/>, <https://onco.cc/cancers/myeloma-transplant-ineligible/>, <https://onco.cc/cancers/plasma-cell-leukaemia/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd38/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/halozyme/> ;
  onco:terms <https://onco.cc/terms/adcc/> ;
  onco:trials <https://onco.cc/trials/perseus/>, <https://onco.cc/trials/cepheus/>, <https://onco.cc/trials/majestec-3/>, <https://onco.cc/trials/nct06868654/>, <https://onco.cc/trials/nct06952478/>, <https://onco.cc/trials/nct06464991/>, <https://onco.cc/trials/nct05438043/>, <https://onco.cc/trials/nct05623020/>, <https://onco.cc/trials/nct04975997/>, <https://onco.cc/trials/nct05020236/>, <https://onco.cc/trials/nct07095452/>, <https://onco.cc/trials/nct06679101/>, <https://onco.cc/trials/nct06868667/>, <https://onco.cc/trials/nct05552222/>, <https://onco.cc/trials/nct05455320/>, <https://onco.cc/trials/nct07393282/>, <https://onco.cc/trials/nct02343042/>, <https://onco.cc/trials/nct03314181/>, <https://onco.cc/trials/nct04133636/>, <https://onco.cc/trials/nct03989414/>, <https://onco.cc/trials/nct06577025/>, <https://onco.cc/trials/nct04782687/>, <https://onco.cc/trials/nct06892522/>, <https://onco.cc/trials/nct06119685/>, <https://onco.cc/trials/nct06953960/>, <https://onco.cc/trials/nct07681596/>, <https://onco.cc/trials/nct04973605/>, <https://onco.cc/trials/nct02773030/>, <https://onco.cc/trials/nct07742215/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aquila-daratumumab-smouldering-nejm-2025/>, <https://onco.cc/key-papers/paper-cassiopeia-lancet-2019/>, <https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/> .